Ido Kanyon

CEO, AusCann


Ido Kanyon is CEO of leading cannabinoid-based pharmaceutical company AusCann, and has extensive pharmaceutical and medical device business experience across the life-science value chain. This covers a comprehensive range of healthcare technologies and commercial strategies from capsules and inhalers to innovative biologics and digital health solutions. Mr. Kanyon has successfully launched innovative medicines globally, providing more patients with access to cost-effective, high-quality, life-changing treatment options.

Prior to AusCann, Mr. Kanyon held a broad range of executive positions at Teva Pharmaceuticals, a NYSE listed company with FY18 revenues of over US$18 billion. This included key leadership roles in Strategic Portfolio Management, Innovative Medicine Brand Marketing, Generics Pharmaceutical Manufacturing, Medical Device Regulatory Affairs and Quality Assurance.

Mr. Kanyon has also worked within an agricultural research organization, led R&D projects for start-up companies, and repeatedly transitioned academic research into robust class III implantable medical devices.

Mr. Kanyon holds a B.Sc. (Agr.) from The Hebrew University of Jerusalem, Israel, an MBA from IE Business School in Spain and Postgraduate training with McKinsey & Co. He holds a fellowship with the College of Physicians of Philadelphia and participates in advisory boards with several technological incubators, such as the leading US accelerator Dreamit Ventures. He has lived and worked in North America, Europe, Asia, and the Middle East.

CEO Roundtable
Back to program
Back to Speakers


AusCann is an Australian Pharmaceutical company bringing together leading expertise and operations across all aspects of the medicinal cannabis value chain.
Read more
Join Us!

Register your interest to attend and stay up to date with our latest news.